Drug Approval | February 13, 2025
FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Prithwish has close to 28 years of experience in a Commercial role
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Exploring new opportunities within the fast-growing market of microfluidics
This facility marks a significant milestone in transforming the global food industr
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
With the addition of Karsanbhai, the Merck board will consist of 13 members
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Subscribe To Our Newsletter & Stay Updated
